Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.41 USD
-1.25 (-0.91%)
Updated May 31, 2024 04:00 PM ET
After-Market: $135.49 +0.08 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 241 - 260 ( 307 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Dropping Coverage
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Lessons of ?854 P2 Set KINECT-3 for Success
Provider: Nomura
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Clean Safety Opens Tourette?s Opportunity
Provider: Nomura
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KINECT 2 Gives Back More Than KINECT 1 Took Away
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Initiating with Buy Rating and $23 TP
Provider: Nomura
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Initiating on US Biotechnology Sector
Provider: Nomura
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KINECT 2 Gives Back More Than KINECT 1 Took Away
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.